NCT06993597 · University of Maryland, Baltimore
Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy
What this study is about
This pilot study evaluates the biomechanical properties of the cornea in glaucoma patients using Brillouin microscopy, a non-contact imaging technique. The study aims to compare corneal stiffness between patients with normal-tension glaucoma, high-tension glaucoma, and healthy controls, and to assess changes in corneal biomechanics following intraocular pressure (IOP)-lowering treatment.
View original scientific description
This pilot study evaluates the biomechanical properties of the cornea in glaucoma patients using Brillouin microscopy, a non-contact imaging technique. The study aims to compare corneal stiffness between patients with normal-tension glaucoma, high-tension glaucoma, and healthy controls, and to assess changes in corneal biomechanics following intraocular pressure (IOP)-lowering treatment. The goal is to determine whether Brillouin-derived biomechanical measurements can serve as biomarkers for glaucoma risk and progression.
Interventions
DRUG
Prostaglandin Analogue -Containing IOP-Lowering Therapy
Subjects with glaucoma may be prescribed prostaglandin analogs as part of their clinical care. This group will be observed longitudinally to assess changes in corneal biomechanics.
DRUG
Beta Blocker
Subjects with glaucoma may be prescribed topical beta blockers as part of their clinical care. This group will be observed longitudinally to assess changes in corneal biomechanics.
DEVICE
Brillouin Microscopy
Brillouin microscopy is a non-contact optical imaging method used to assess the biomechanical properties of the cornea in vivo with three-dimensional resolution. It will be used to evaluate corneal stiffness in all study subjects.
Primary outcome measures
Change in Corneal Biomechanical Modulus
Time frame: Baseline, 3 weeks, and 6 weeks
Brillouin microscopy will be used to measure the corneal modulus of elasticity. The primary outcome is the change in corneal stiffness (Brillouin shift in MHz) across time points in subjects treated with prostaglandin analogs versus beta blockers, and between groups at baseline (NTG, HTG, controls).
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- \- Age 18 years or older Diagnosis of primary open angle glaucoma (POAG) or no history of glaucoma (for controls) Open angle on gonioscopy (Shaffer grade 3 or 4) Best-corrected visual acuity of 20/25 or better Refractive error between +3.00 and -5.00 diopters No prior use of topical glaucoma medications Diagnosis of: High Tension Glaucoma (IOP ≥ 22 mmHg on 3 visits) Normal Tension Glaucoma (IOP ≤ 21 mmHg on 3 visits) OR age-matched control with normal optic nerve and visual fields
Exclusion criteria
- Corneal abnormalities or conditions interfering with Brillouin or applanation tonometry Retinal diseases affecting RNFL (e.g., macular traction) History of ocular surgery or laser Diagnosis of diabetes History of uveitis History of prolonged steroid use Neurodegenerative or systemic diseases (e.g., multiple sclerosis, Alzheimer's, Parkinson's, schizophrenia) Unreliable visual fields Contraindications to beta blockers (e.g., bradycardia, severe pulmonary disease) Moderate to severe glaucoma (per Hodapp-Anderson-Parrish criteria) History of contact lens use Low blood pressure
Where
- Baltimore, Maryland
Collaborators
National Eye Institute (NEI)
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Sep 9, 2025 · Source of record for eligibility and locations